



| | |
|--|--|
| Division: Pharmacy Policy | Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria |
| Original Development Date: Original Effective Date: Revision Date: | January 11, 2021 |

LUCEMYRA™ (lofexidine)

LENGTH OF AUTHORIZATION: Initial therapy: 7 days
Continuation of therapy: 7 days

REVIEW CRITERIA:

- Patient is 18 years of age or older
- Patient has a confirmed diagnosis of opioid dependence or opioid use disorder
- Prescribe by or in consultation with a pain management or addiction specialist
- Patient is undergoing or is scheduled to undergo abrupt opioid discontinuation
- Patient has tried and failed clonidine within the last 6 months. Contraindications and/or clinically significant adverse events must be documented OR documentation that Lucemyra was initiated in an emergency department
- Patient has a normal QT interval

CONTINUATION OF THERAPY:

- Documentation of positive patient response

DOSING AND ADMINISTRATION:

- Available as 0.18mg tablets
- Starting dose: 3 tablets orally 4 times a day at 5-6 hours intervals for up to 14 days.
- Maximum dose: Maximum single dose is 4 tablets per dose; maximum daily dose is 16 tablets per day